CZC-54252 is a potent, selective, and metabolically stable LRRK2 inhibitor (Leucine-rich repeat kinase-2) with IC50 of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2 respectively.

MLi-2 (MLi2) is a novel, highly potent, orally bioactive, and selective LRRK2 (Leucine-Rich Repeat Kinase 2) kinase inhibitor (IC50 = 0.76 nM) with CNS (central nervous system) activity, and thus has the potential for treating Parkinson’s disease.

CZC-25146 is a potent, selective, and metabolically stable LRRK2 inhibitor (Leucine-rich repeat kinase-2) with IC50 of 4.76 nM and 6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.

PF-06447475 (PF06447475) is a novel, highly potent, selective and brain penetrable inhibitor of Leucine rich repeat kinase 2 (LRRK2) with anti-PD activity.

CZC-25146 is a potent and selective LRRK2 inhibitor.